DHL—Global express delivery and logistics services provider —announced recently that its DHL Express subsidiary is rolling out a new offering which is aimed towards pharmaceutical and clinical research sector shippers connecting the United States and Brazil.
Entitled DHL Medical Express Service (WMX), DHL announced this service was introduced in November 2018 as a pilot program. The program concentrates on enhanced customer requirement for faster and more regular lead times in reply to regulatory complexities that can frequently hold up exports, adding that this service offers significant benefits for clinical trial patients, as “temperature-sensitive biological commodities and new patient-specific medications will be in the correct hands, exactly when required.”
According to Mike Parra, CEO of DHL Express Americas, DHL Medical Express remains to meet the requirements of the pharmaceutical industry and clinical research sectors with forward-thinking, creative solutions. The launch of this service in Brazil develops towards their ambition to give logistics solutions in the Latin and South American countries where most clinical trials are conducted. DHL’s powerful international network, compliant certifications and the blend of responsiveness, reliability, and cost-effectiveness will facilitate this service to be profitable to all stakeholders in the clinical trial assessment chain.
Brian Bralynski Director of Life Sciences Healthcare Americas, DHL Express, stated that the requirement for this service was encouraged by the increase of demand for quicker, more anticipated lead times of transports for consumers in the pharmaceutical and clinical research areas. He also noted that the pilot program lasted 60 days and included three shippers.
